Arcturus Therapeutics ( (ARCT) ) has released its Q2 earnings. Here is a breakdown of the information Arcturus Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arcturus Therapeutics Holdings Inc., based in San Diego, is a commercial mRNA medicines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, utilizing its proprietary LUNAR® and STARR® mRNA technologies.
In its latest earnings report, Arcturus Therapeutics announced significant progress in its clinical pipeline, including advancements in cystic fibrosis and OTC deficiency trials, as well as positive results from its seasonal flu vaccine candidate. Despite a decrease in revenue, the company has managed to reduce its net loss compared to the previous year.
Key financial metrics revealed a revenue of $28.3 million for the second quarter of 2025, a decline from the previous year, primarily due to reduced activity in the CSL collaboration. However, the company successfully cut operating expenses to $39.9 million, down from $71.0 million in the same quarter last year, contributing to a reduced net loss of $9.2 million. Arcturus also highlighted its robust cash position, with a runway extending into 2028.
Strategically, Arcturus is making strides in its clinical trials, with the cystic fibrosis Phase 2 trial expected to complete enrollment by the end of 2025 and the OTC deficiency Phase 3 trial design alignment anticipated in the first half of 2026. The company also reported positive Phase 1 results for its seasonal flu vaccine and expects Phase 1 results for its pandemic flu candidate later in 2025.
Looking forward, Arcturus remains focused on advancing its clinical programs and achieving regulatory milestones. The management is optimistic about its pipeline’s potential and is preparing for pivotal trials and regulatory discussions in the coming years, aiming to bring innovative mRNA therapies to market.